This week, a jury found Elizabeth Holmes, who created the defunct diagnostics company Theranos, guilty of defrauding investors. While running the company, she claimed Theranos had proprietary technology that could test someone for a variety of ailments using just a drop of blood. That wasn’t true. So what does the jury’s decision mean for the future of investing in biotech startups? Elizabeth Lopatto is deputy editor at The Verge and covered the trial closely for several months. She said that a major theme during the trial was how Holmes spoke with investors.